Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure

被引:22
|
作者
Cohen, DS [1 ]
Mathis, JE [1 ]
Dotson, RA [1 ]
Graybill, SR [1 ]
Wosu, NJ [1 ]
机构
[1] Novartis Pharmaceut Corp, Dept Cardiovasc Pharmacol, Summit, NJ 07901 USA
关键词
angiotensin-converting enzyme inhibition; neutral endopeptidase inhibition; remnant kidney; reduced renal mass;
D O I
10.1097/00005344-199807000-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of these studies was to compare the effects of CGS 30440 (CGS), a dual angiotensin-converting enzyme inhibitor (ACEI)/neutral endopeptidase inhibitor (NEPI) to benazepril (BZ), an ACEI, in a model of five-sixths nephrectomy. The doses of BZ and CGS 30440 tested were 6.5 mu mol/kg/day and 2.2 mu mol/kg/day. Drugs or vehicle (V) were administered subcutaneously for 6 weeks with dosing initiated 1 week after renal mass reduction. At 6 weeks or receiving drug (7 weeks after five-sixths nephrectomy), CGS/6.5 and BZ/6.5 and CGS/2.2 maintained systolic blood pressures (SBP) at presurgical values. BZ/2.2 did not reduce SEP and was similar to the V group. Urinary protein excretion increased > 10-fold in the V-treated group. BZ, at either dose, reduced the proteinuria slightly. CGS/6.5 and CGS/2.2 caused significant (p < 0.05) reductions in proteinuria. Creatinine clearance (Cr-cl), was reduced by 82% in V, 65 and 61% in the CGS/6.5 and CGS/2.2 groups, and by 69 and 74% in the BZ/6.5 and BZ/2.2 groups, respectively. Both CGS treatments improved the fractional excretion of Naf (%FENa) significantly from the BZ and V groups. The %FENa for BZ at either dose did not differ from that of V. Elevated urinary cyclic guanosine monophosphate (cGMP), an indicator suggesting increased intrarenal levels of atrial natriuretic peptide (ANP), was observed only in the CGS groups. Histologic examination indicated that BZ/6.5 reduced glomerular sclerosis and the extent of tubular dilation, whereas BZ/2.2 had little effect. CGS, especially at the high dose, virtually normalized the glomerular and tubular pathology. Compared with BZ, CGS 30440 treatment further diminished tubular dilation and proteinaceous cast formation. These tubular effects are consistent with some of the renal actions of ANP. The results from these studies indicate that CGS 30440, a combined ACEI/NEPI, conferred a greater renal protective effect than did ACE inhibition alone. Key Words: Angiotensin-converting enzyme inhibition-Neutral endopeptidase inhibition-Remnant kidney-Reduced renal mass.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 50 条
  • [1] CGS 30440: A dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11
    Cohen, DS
    Fink, CA
    Trapani, AJ
    Webb, RL
    Zane, PA
    Chatelain, RE
    CARDIOVASCULAR DRUG REVIEWS, 1999, 17 (01): : 16 - 38
  • [2] Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11
    Chatelain, RE
    Ghai, RD
    Trapani, AJ
    Odorico, LM
    Dardik, BN
    De Lombaert, S
    Lappe, RW
    Fink, CA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 284 (03): : 974 - 982
  • [3] Efficient large scale preparation of neutral endopeptidase/angiotensin-converting enzyme dual inhibitor CGS30440
    Johnson, EP
    Cantrell, WR
    Jenson, TM
    Miller, SA
    Parker, DJ
    Reel, NM
    Sylvester, LG
    Szendroi, RJ
    Vargas, KJ
    Xu, J
    Carlson, JA
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 1998, 2 (04) : 238 - 244
  • [4] Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase 24.11.
    Chatelain, RE
    Odorico, LM
    Ghai, RD
    Trapani, AJ
    Fink, CA
    Lappe, RW
    FASEB JOURNAL, 1996, 10 (03): : 4038 - 4038
  • [5] Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats
    Webb, RL
    Abramson, ML
    Beil, ME
    Odorico, LM
    Chatelain, RE
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (05) : 632 - 642
  • [6] CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme
    Battistini, Bruno
    Daull, Philippe
    Jeng, Arco Y.
    CARDIOVASCULAR DRUG REVIEWS, 2005, 23 (04): : 317 - 330
  • [7] Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome
    Eizenberg, Yoav
    Grossman, Ehud
    Peleg, Edna
    Shabtai, Zehava
    Sharabi, Yehonatan
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) : 227 - 231
  • [8] Neutral endopeptidase inhibition augments the vascular actions of bradykinin in patients with heart failure on chronic angiotensin-converting enzyme inhibitor therapy
    Cruden, NL
    Fox, KAA
    Newby, DE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 158A - 159A
  • [9] Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia
    Chodjania, Y
    Tharaux, PL
    Ragueneau, I
    Dussaule, JC
    Picker, JL
    Funck-Brentano, C
    Jaillon, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (06) : 468 - 478
  • [10] ROLE OF ANGIOTENSIN-CONVERTING ENZYME IN THE VASCULAR EFFECTS OF AN ENDOPEPTIDASE-24.15 INHIBITOR
    TELFORD, SE
    SMITH, AI
    LEW, RA
    PERICH, RB
    MADDEN, AC
    EVANS, RG
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (06) : 1185 - 1192